Abstract
Finding antivirals to reduce coronavirus disease 2019 (COVID-19) morbidity and mortality has been challenging. Large randomized clinical trials that aimed to test four repurposed drugs, hydroxychloroquine, lopinavir-ritonavir, interferon beta 1a, and remdesivir, have shown that these compounds lack an impact on the COVID-19 course. Although the phase III COVID-19 vaccine trial results are encouraging, the search for effective COVID-19 therapeutics should not stop. Recently, plitidepsin (aplidin) demonstrated highly effective preclinical activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Its antiviral activity was 27.5-fold more potent than that of remdesivir (K. M. White, R. Rosales, S. Yildiz, T. Kehrer, et al., Science, 2021, https://science.sciencemag.org/content/early/2021/01/22/science.abf4058). Plitidepsin, a repurposed drug developed for the treatment of multiple myeloma, targets the host translation cofactor eEF1A. Plitidepsin has shown efficacy in animal models and phase I/II human trials. Although plitidepsin is administered intravenously and its toxicity profile remains to be fully characterized, this compound may be a promising alternative COVID-19 therapeutic.
Keywords: COVID-19; experimental therapeutics; plitidepsin.
【저자키워드】 COVID-19, breath, Plitidepsin, experimental therapeutics, 【초록키워드】 Treatment, coronavirus disease, SARS-CoV-2, randomized clinical trial, Coronavirus disease 2019, Efficacy, coronavirus, COVID-19 vaccine, Trial, Repurposed drugs, Hydroxychloroquine, Antiviral, translation, Lopinavir, Ritonavir, Remdesivir, Toxicity, animal model, animal models, antiviral activity, severe acute respiratory syndrome Coronavirus, COVID-19 therapeutics, Multiple myeloma, morbidity, therapeutic, target, morbidity and mortality, Plitidepsin, trials, Lopinavir-ritonavir, experimental therapeutics, cofactor, interferon beta, Science, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, white, these compounds, finding, intravenously, aplidin, Administered, Host, effective, Large randomized clinical trials, Course, shown, lack, characterized, demonstrated, these compound, reduce, 【제목키워드】 drug,